Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33

Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13

Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. Ann Surg (2016) 0.99

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics (2014) 0.98

Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. Gut Liver (2015) 0.97

Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clin Cancer Res (2015) 0.93

GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg (2015) 0.93

Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91

Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol (2014) 0.90

Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int (2014) 0.88

Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One (2014) 0.88

Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg (2014) 0.88

Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol (2014) 0.83

Pancreatic adenocarcinoma pathology: changing "landscape". J Gastrointest Oncol (2015) 0.82

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep (2017) 0.80

Diagnosis and management of cystic lesions of the pancreas. J Gastrointest Oncol (2015) 0.79

GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch (2015) 0.79

The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol (2016) 0.79

[Classification and malignant potential of pancreatic cystic tumors]. Pathologe (2015) 0.79

Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med (2015) 0.78

Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2016) 0.76

Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. Hum Pathol (2015) 0.75

Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol (2017) 0.75

Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75

Clinicopathological implications of GNAS in Ewing sarcoma. Oncol Lett (2016) 0.75

Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch (2017) 0.75

Smoking is not associated with severe dysplasia or invasive carcinoma in resected intraductal papillary mucinous neoplasms. J Gastrointest Surg (2014) 0.75

Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. J Cancer Res Clin Oncol (2016) 0.75

Endoscopic Management of Pancreatic Cysts. Dig Dis Sci (2017) 0.75

Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct. World J Surg (2015) 0.75

Pancreatic Cancer Screening. Curr Treat Options Gastroenterol (2017) 0.75

Molecular diagnostics of pancreatic cysts. Langenbecks Arch Surg (2013) 0.75

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51

Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76

Minireview: GNAS: normal and abnormal functions. Endocrinology (2004) 2.50

Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45

Incidental pancreatic cysts: do we really know what we are watching? Pancreatology (2010) 2.22

Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17

Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09

Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96

Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery (2012) 1.76

Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg (2007) 1.60

Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab (2003) 1.36

Activating mutations of Gsalpha in kidney cancer. J Urol (2006) 1.31

GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25

Frequent activating GNAS mutations in villous adenoma of the colorectum. J Pathol (2012) 1.22

Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22

Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas (2005) 1.16

A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn (2012) 1.06

Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary (2007) 1.03

Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J (2009) 0.97

Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. Gynecol Oncol (2010) 0.90